U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Google Secures Pentagon AI Deal for Classified Projects 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
SAN DIEGO, April 20, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will present at the 5th Annual Cell & Gene Therapy Investor Day in Boston on Thursday, April 27, 2017 at 9:25 a.m. ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cells, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200 [email protected]
